The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.

Researchers said the study backs up anecdotal evidence from patients and doctors that semaglutide can lead to a sudden loss of longing for alcoholic drinks ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

(Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

New research suggests semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could help people reduce their alcohol consumption.

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...